Novavax and Sanofi enter into a $1.2 billion deal for COVID-19 and flu vaccine development
The agreement includes an upfront payment of $500 million from Sanofi to Novavax, with potential payments of up to $700 million based on milestones
Novavax and Sanofi Announce Landmark Deal for COVID-19 and Flu Vaccines
In a major development, Novavax and Sanofi have entered into a $1.2 billion deal to co-develop new vaccines, including a combination COVID-19 and flu vaccine. The agreement includes an upfront payment of $500 million from Sanofi to Novavax, with potential payments of up to $700 million based on milestones.
Novavax's CEO, John C. Jacobs, expressed his excitement about the partnership:
Novavax signed a deal with Sanofi for co-commercialization of its Covid vaccine and development of combination shots starting next year.
Sanofi will pay Novavax an upfront payment of $500 million and up to $1.2 billion in payments for development, regulatory and launch milestones.
Novavax is entitled to royalty payments on Sanofi’s sales of its Covid vaccine and combination shots targeting coronavirus and the flu.
Sanofi will take a less than 5% stake in Novavax.
Novavax will lead the commercialization of its Covid shot for the rest of this year, then transfer most responsibility to Sanofi in 2025.
Sanofi can develop products combining its flu shot or other vaccines with Novavax’s Covid jab and use Novavax’s Matrix-M adjuvant to create new vaccine products.
Novavax expects to start a late-stage trial on its own combination vaccine targeting Covid and the flu, as well as a standalone flu shot, later this year.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
The article contains an appeal to authority fallacy when it states 'Health officials view the vaccine as a valuable alternative for people who don't want to take messenger RNA jabs from Pfizer and Moderna.' This statement implies that the opinion of health officials is a valid reason for Novavax's vaccine being valuable, but it does not provide any evidence or reasoning beyond that. Additionally, there are several instances of inflammatory rhetoric used in the article such as 'strugggling vaccine maker' and 'turning point', but these do not constitute logical fallacies.
]Health officials view the vaccine as a valuable alternative for people who don’t want to take messenger RNA jabs from Pfizer and Moderna.[/
:max_bytes(150000):strip_icc()/GettyImages-1239401338-13e17db8844241f1a997d6ebc04cc337.jpg)
